23 results on '"Alberti AB"'
Search Results
2. Immunogenetic factors, HCV genotype and HCV recurrence after liver transplantation
- Author
-
Belli, LS, primary, Zavaglia, C, additional, Alberti, AB, additional, Silini, E, additional, Poli, F, additional, De Carlis, L, additional, Rondinara, GF, additional, Scalamogna, M, additional, Forti, D, additional, and Idèo, G, additional
- Published
- 1998
- Full Text
- View/download PDF
3. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial
- Author
-
Caraceni, Paolo, Riggio, Oliviero, Angeli, Paolo, Alessandria, Carlo, Neri, Sergio, Foschi, Francesco G, Levantesi, Fabio, Airoldi, Aldo, Boccia, Sergio, Svegliati-Baroni, Gianluca, Fagiuoli, Stefano, Romanelli, Roberto G, Cozzolongo, Raffaele, Di Marco, Vito, Sangiovanni, Vincenzo, Morisco, Filomena, Toniutto, Pierluigi, Tortora, Annalisa, De Marco, Rosanna, Angelico, Mario, Cacciola, Irene, Elia, Gianfranco, Federico, Alessandro, Massironi, Sara, Guarisco, Riccardo, Galioto, Alessandra, Ballardini, Giorgio, Rendina, Maria, Nardelli, Silvia, Piano, Salvatore, Elia, Chiara, Prestianni, Loredana, Cappa, Federica Mirici, Cesarini, Lucia, Simone, Loredana, Pasquale, Chiara, Cavallin, Marta, Andrealli, Alida, Fidone, Federica, Ruggeri, Matteo, Roncadori, Andrea, Baldassarre, Maurizio, Tufoni, Manuel, Zaccherini, Giacomo, Bernardi, Mauro, Domenicali, Marco, Giannone, Ferdinando A, Merli, Manuela, Gioia, Stefania, Fasolato, Silvano, Sticca, Antonietta, Campion, Daniela, Risso, Alessandro, Saracco, Giorgio M, Maiorca, Daniela, Rizzotto, Agostino, Lanzi, Arianna, Neri, Elga, Visani, Anna, Mastroianni, Antonio, Alberti, Alberto B, Mazzarelli, Chiara, Vangeli, Marcello, Marzioni, Marco, Capretti, Francesca, Kostandini, Alba, Magini, Giulia, Colpani, Maria, Laffi, Giacomo, Gabbani, Tommaso, Marsico, Maria, Zappimbulso, Marianna, Petruzzi, Josè, Calvaruso, Vincenza, Parrella, Giovanni, Caporaso, Nicola, Auriemma, Francesco, Guarino, Maria, Pugliese, Fabio, Gasbarrini, Antonio, Leo, Pietro, De Leonardis, Francesco, Pecchioli, Alessandra, Rossi, Piera, Raimondo, Giovanni, Negri, Elisa, Dallio, Marcello, Loguercio, Carmelina, Conte, Dario, Celli, Natascia, Bringiotti, Roberto, Castellaneta, Nicola M, Salerno, Francesco, ANSWER Study Investigators, Caraceni, Paolo, Riggio, Oliviero, Angeli, Paolo, Alessandria, Carlo, Neri, Sergio, Foschi, Francesco G, Levantesi, Fabio, Airoldi, Aldo, Boccia, Sergio, Svegliati-Baroni, Gianluca, Fagiuoli, Stefano, Romanelli, Roberto G, Cozzolongo, Raffaele, Di Marco, Vito, Sangiovanni, Vincenzo, Morisco, Filomena, Toniutto, Pierluigi, Tortora, Annalisa, De Marco, Rosanna, Angelico, Mario, Cacciola, Irene, Elia, Gianfranco, Federico, Alessandro, Massironi, Sara, Guarisco, Riccardo, Galioto, Alessandra, Ballardini, Giorgio, Rendina, Maria, Nardelli, Silvia, Piano, Salvatore, Elia, Chiara, Prestianni, Loredana, Cappa, Federica Mirici, Cesarini, Lucia, Simone, Loredana, Pasquale, Chiara, Cavallin, Marta, Andrealli, Alida, Fidone, Federica, Ruggeri, Matteo, Roncadori, Andrea, Baldassarre, Maurizio, Tufoni, Manuel, Zaccherini, Giacomo, Bernardi, Mauro, Domenicali, Marco, Giannone, Ferdinando A, Merli, Manuela, Gioia, Stefania, Fasolato, Silvano, Sticca, Antonietta, Campion, Daniela, Risso, Alessandro, Saracco, Giorgio M, Maiorca, Daniela, Rizzotto, Agostino, Lanzi, Arianna, Neri, Elga, Visani, Anna, Mastroianni, Antonio, Alberti, Alberto B, Mazzarelli, Chiara, Vangeli, Marcello, Marzioni, Marco, Capretti, Francesca, Kostandini, Alba, Magini, Giulia, Colpani, Maria, Laffi, Giacomo, Gabbani, Tommaso, Marsico, Maria, Zappimbulso, Marianna, Petruzzi, Josè, Calvaruso, Vincenza, Parrella, Giovanni, Caporaso, Nicola, Auriemma, Francesco, Guarino, Maria, Pugliese, Fabio, Gasbarrini, Antonio, Leo, Pietro, De Leonardis, Francesco, Pecchioli, Alessandra, Rossi, Piera, Raimondo, Giovanni, Negri, Elisa, Dallio, Marcello, Loguercio, Carmelina, Conte, Dario, Celli, Natascia, Bringiotti, Roberto, Castellaneta, Nicola M, Salerno, Francesco, Caraceni P1, Riggio O2, Angeli P3, Alessandria C4, Neri S5, Foschi FG6, Levantesi F7, Airoldi A8, Boccia S9, Svegliati-Baroni G10, Fagiuoli S11, Romanelli RG12, Cozzolongo R13, Di Marco Vito, Sangiovanni V15, Morisco F16, Toniutto P17, Tortora A18, De Marco R19, Angelico M20, Cacciola I21, Elia G22, Federico A23, Massironi S24, Guarisco R25, Galioto A26, Ballardini G27, Rendina M28, Nardelli S2, Piano S3, Elia C4, Prestianni L5, Cappa FM6, Cesarini L8, Simone L9, Pasquale C2, Cavallin M3, Andrealli A4, Fidone F5, Ruggeri M29, Roncadori A30, Baldassarre M1, Tufoni M1, Zaccherini G1, Bernardi M31, Domenicali M, Giannone FA, Merli M, Gioia S, Fasolato S, Sticca A, Campion D, Risso A, Saracco GM, Maiorca D, Rizzotto A, Lanzi A, Neri E, Visani A, Mastroianni A, Alberti AB, Mazzarelli C, Vangeli M, Marzioni M, Capretti F, Kostandini A, Magini G, Colpani M, Laffi G, Gabbani T, Marsico M, Zappimbulso M, Petruzzi J, Calvaruso Vincenza, Parrella G, Caporaso N, Auriemma F, Guarino M, Pugliese F, Gasbarrini A, Leo P, De Leonardis F, Pecchioli A, Rossi P, Raimondo G, Negri E, Dallio M, Loguercio C, Conte D, Celli N, Bringiotti R, Castellaneta NM, Salerno F., Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, Levantesi F, Airoldi A, Boccia S, Svegliati-Baroni G, Fagiuoli S, Romanelli RG, Cozzolongo R, Di Marco V, Sangiovanni V, Morisco F, Toniutto P, Tortora A, De Marco R, Angelico M, Cacciola I, Elia G, Federico A, Massironi S, Guarisco R, Galioto A, Ballardini G, Rendina M, Nardelli S, Piano S, Elia C, Prestianni L, Cappa FM, Cesarini L, Simone L, Pasquale C, Cavallin M, Andrealli A, Fidone F, Ruggeri M, Roncadori A, Baldassarre M, Tufoni M, Zaccherini G, Bernardi M, Domenicali M, Giannone FA, Merli M, Gioia S, Fasolato S, Sticca A, Campion D, Risso A, Saracco GM, Maiorca D, Rizzotto A, Lanzi A, Neri E, Visani A, Mastroianni A, Alberti AB, Mazzarelli C, Vangeli M, Marzioni M, Capretti F, Kostandini A, Magini G, Colpani M, Laffi G, Gabbani T, Marsico M, Zappimbulso M, Petruzzi J, Calvaruso V, Parrella G, Caporaso N, Auriemma F, Guarino M, Pugliese F, Gasbarrini A, Leo P, De Leonardis F, Pecchioli A, Rossi P, Raimondo G, Negri E, Dallio M, Loguercio C, Conte D, Celli N, Bringiotti R, Castellaneta NM, Salerno F., Caraceni, P, Riggio, O, Angeli, P, Alessandria, C, Neri, S, Foschi, F, Levantesi, F, Airoldi, A, Boccia, S, Svegliati-Baroni, G, Fagiuoli, S, Romanelli, R, Cozzolongo, R, Di Marco, V, Sangiovanni, V, Morisco, F, Toniutto, P, Tortora, A, De Marco, R, Angelico, M, Cacciola, I, Elia, G, Federico, A, Massironi, S, Guarisco, R, Galioto, A, Ballardini, G, Rendina, M, Nardelli, S, Piano, S, Elia, C, Prestianni, L, Cappa, F, Cesarini, L, Simone, L, Pasquale, C, Cavallin, M, Andrealli, A, Fidone, F, Ruggeri, M, Roncadori, A, Baldassarre, M, Tufoni, M, Zaccherini, G, Bernardi, M, Domenicali, M, Giannone, F, Merli, M, Gioia, S, Fasolato, S, Sticca, A, Campion, D, Risso, A, Saracco, G, Maiorca, D, Rizzotto, A, Lanzi, A, Neri, E, Visani, A, Mastroianni, A, Alberti, A, Mazzarelli, C, Vangeli, M, Marzioni, M, Capretti, F, Kostandini, A, Magini, G, Colpani, M, Laffi, G, Gabbani, T, Marsico, M, Zappimbulso, M, Petruzzi, J, Calvaruso, V, Parrella, G, Caporaso, N, Auriemma, F, Guarino, M, Pugliese, F, Gasbarrini, A, Leo, P, De Leonardis, F, Pecchioli, A, Rossi, P, Raimondo, G, Negri, E, Dallio, M, Loguercio, C, Conte, D, Celli, N, Bringiotti, R, Castellaneta, N, and Salerno, F
- Subjects
Liver Cirrhosis ,Male ,Time Factors ,Cirrhosis ,Kaplan-Meier Estimate ,law.invention ,ascites ,0302 clinical medicine ,Hepatorenal syndrome ,Randomized controlled trial ,Furosemide ,law ,Ascites ,Clinical endpoint ,Paracentesis ,Diuretics ,albumin, decompensated cirrhosi ,Mineralocorticoid Receptor Antagonists ,Settore MED/12 - Gastroenterologia ,Medicine (all) ,Hazard ratio ,General Medicine ,Middle Aged ,Survival Rate ,030220 oncology & carcinogenesis ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,Quality-Adjusted Life Years ,medicine.symptom ,Hyponatremia ,medicine.medical_specialty ,03 medical and health sciences ,Albumins ,Internal medicine ,medicine ,Humans ,Survival rate ,albumin ,Aged ,business.industry ,cirrhosis ,medicine.disease ,Clinical trial ,albumin, cirrhosis, ascites, liver decompensation ,Quality of Life ,Hyperkalemia ,business ,Esophagus Varices, Portal Hypertension, Varicosis - Abstract
Background Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issue. Methods We did an investigator-initiated multicentre randomised, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly) for up to 18 months. The primary endpoint was 18-month mortality, evaluated as difference of events and analysis of survival time in patients included in the modified intention-to-treat and per-protocol populations. This study is registered with EudraCT, number 2008–000625–19, and ClinicalTrials.gov, number NCT01288794. Findings From April 2, 2011, to May 27, 2015, 440 patients were randomly assigned and 431 were included in the modified intention-to-treat analysis. 38 of 218 patients died in the SMT plus HA group and 46 of 213 in the SMT group. Overall 18-month survival was significantly higher in the SMT plus HA than in the SMT group (Kaplan-Meier estimates 77% vs 66%; p=0·028), resulting in a 38% reduction in the mortality hazard ratio (0·62 [95% CI 0·40–0·95]). 46 (22%) patients in the SMT group and 49 (22%) in the SMT plus HA group had grade 3–4 non-liver related adverse events. Interpretation In this trial, long-term HA administration prolongs overall survival and might act as a disease modifying treatment in patients with decompensated cirrhosis. Funding Italian Medicine Agency. Copyright © 2018 Elsevier Ltd. All rights reserved.
- Published
- 2018
4. Deviant Peer Behavior and Adolescent Delinquency: Protective Effects of Inhibitory Control, Planning, or Decision Making?
- Author
-
Hinnant JB and Forman-Alberti AB
- Subjects
- Adolescent, Female, Humans, Inhibition, Psychological, Juvenile Delinquency statistics & numerical data, Legal Guardians psychology, Male, National Institute of Child Health and Human Development (U.S.) organization & administration, Peer Group, Perception physiology, Problem Behavior psychology, Self Report, Social Class, United States epidemiology, Adolescent Behavior psychology, Antisocial Personality Disorder psychology, Decision Making physiology, Juvenile Delinquency psychology
- Abstract
We examined relations between adolescent perceptions of deviant peer behavior and delinquency as moderated by inhibitory control, planning, and decision making in the National Institute of Child Health and Human Development (NICHD) Study of Early Child Care and Youth Development at age 15 (N = 991). Adolescents reported perceptions of deviant peer behavior. Inhibitory control, planning, and decision making were assessed behaviorally. Delinquency was evaluated with a latent variable comprised of parent-guardian perceptions of adolescent delinquency and adolescent self-reports. Only inhibitory control moderated the relationship between deviant peer behavior and delinquency, showing that better inhibition protected against delinquency in contexts of high levels of adolescent perceptions of deviant peer behavior. Findings are discussed in the context of theories of adolescent delinquency and risk taking., (© 2018 Society for Research on Adolescence.)
- Published
- 2019
- Full Text
- View/download PDF
5. Approach Behaviour, Stress and Substance Use in Young Adults.
- Author
-
Hinnant JB, Forman-Alberti AB, Aquino AK, Szollos S, and Degnan KA
- Subjects
- Adult, Female, Humans, Male, Young Adult, Social Behavior, Stress, Psychological psychology, Substance-Related Disorders psychology
- Abstract
We investigated the interaction between approach behaviours (measured through performance on a resource-gathering task) and self-reported global life stress to predict substance use. Our hypothesis that high levels of approach behaviour in combination with high life stress would predict elevated substance use was guided by the reinforcement sensitivity theory (Gray & McNaughton, ). Ninety-three young adult students (61 women and 32 men) completed a computerized resource-gathering task and questionnaires assessing global life stress and substance use. Consistent with the hypothesis, approach behaviour was positively related to substance use for individuals with high life stress. The findings suggest that person by environment interactions are useful in understanding substance use and we discuss how approach-motivated individuals may arrive at different substance use outcomes as a function of stressful contexts. Copyright © 2016 John Wiley & Sons, Ltd., (Copyright © 2016 John Wiley & Sons, Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
6. Change of liver transplantation list composition: Pre versus post direct-acting antivirals era. The Niguarda Hospital experience.
- Author
-
Viganò R, Mazzarelli C, Alberti AB, and Perricone G
- Subjects
- Hospitals, Humans, Italy, Antiviral Agents therapeutic use, Hepatitis C drug therapy, Liver Transplantation statistics & numerical data, Waiting Lists
- Published
- 2017
- Full Text
- View/download PDF
7. Links between autonomic activity and implicit learning.
- Author
-
Forman-Alberti AB and Hinnant JB
- Subjects
- Adult, Female, Humans, Male, Uncertainty, Young Adult, Association Learning physiology, Autonomic Nervous System physiology, Decision Making physiology, Probability Learning, Respiratory Sinus Arrhythmia physiology
- Abstract
The somatic marker hypothesis posits that autonomic activity occurring in response to specific stimuli aids in implicit learning, the learning of information without explicit awareness of what has been learned. This study investigated whether respiratory sinus arrhythmia (RSA), a measure of autonomic nervous system activity, predicted changes in implicit learning. The interaction of resting RSA and RSA reactivity (change in RSA during the implicit learning task) was associated with changes in implicit learning, with those who had higher resting RSA and greater RSA withdrawal during the task performing better. These findings contribute to a better understanding of the autonomic processes that may underlie implicit learning and are discussed in relation to potential links between autonomic activity, implicit learning, and decision making., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
8. Approach behavior and sympathetic nervous system reactivity predict substance use in young adults.
- Author
-
Hinnant JB, Forman-Alberti AB, Freedman A, Byrnes L, and Degnan KA
- Subjects
- Adolescent, Choice Behavior, Female, Humans, Male, Regression Analysis, Rest, Students, Surveys and Questionnaires, Universities, Avoidance Learning physiology, Substance-Related Disorders diagnosis, Substance-Related Disorders pathology, Substance-Related Disorders psychology, Sympathetic Nervous System physiopathology
- Abstract
A behavioral measure of approach (performance on a resource gathering task) in combination with sympathetic nervous system (SNS) reactivity was used to predict substance use in a sample of young adults (n=93). Pre-ejection period reactivity (PEP-R), a cardiac index of SNS reactivity, was recorded during the resource gathering task (task PEP - resting PEP). Higher levels of approach behaviors on the task in combination with less PEP-R (blunted SNS reactivity) predicted the highest levels of substance use. Findings are discussed in the context of behavioral and physiological systems of approach and avoidance., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
9. Event simultaneity does not eliminate age deficits in implicit probabilistic sequence learning.
- Author
-
Forman-Alberti AB, Seaman KL, Howard DV, and Howard JH Jr
- Subjects
- Adolescent, Age Factors, Aged, Aged, 80 and over, Cues, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Reaction Time physiology, Young Adult, Aging physiology, Association Learning physiology
- Abstract
Recent studies have shown age-related deficits in learning subtle probabilistic sequential relationships. However, virtually all sequence learning studies have displayed successive events one at a time. Here we used a modified Triplets Learning Task to investigate if an age deficit occurs even when sequentially-presented predictive events remain in view simultaneously. Twelve young and 12 old adults observed two cue events and responded to a target event on each of a series of trials. All three events remained in view until the subject responded. Unbeknownst to participants, the first cue predicted one of four targets on 80% of the trials. Learning was indicated by faster and more accurate responding to these high-probability targets than to low-probability targets. Results revealed age deficits in sequence learning even with this simultaneous display, suggesting that age differences are not due solely to general processing declines, but rather reflect an age-related deficit in associative learning.
- Published
- 2014
- Full Text
- View/download PDF
10. Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study.
- Author
-
Belli LS, Volpes R, Graziadei I, Fagiuoli S, Starkel P, Burra P, Alberti AB, Gridelli B, Vogel W, Pasulo L, De Martin E, Guido M, De Carlis L, Lerut J, Cillo U, Burroughs AK, and Pinzello G
- Subjects
- Adult, Aged, Biopsy, Chi-Square Distribution, Disease Progression, Female, Genotype, Hepacivirus genetics, Hepatitis C complications, Humans, Interferon alpha-2, Liver Cirrhosis virology, Liver Transplantation, Logistic Models, Male, Middle Aged, RNA, Viral blood, Recombinant Proteins therapeutic use, Recurrence, Viral Load, Antiviral Agents therapeutic use, Hepatitis C drug therapy, Interferon-alpha therapeutic use, Liver pathology, Liver Cirrhosis pathology, Polyethylene Glycols therapeutic use, Ribavirin therapeutic use
- Abstract
Backgrounds/aims: We evaluated the effect of antiviral therapy on fibrosis progression in patients with histological features of mild/moderate HCV disease recurrence defined by a Grading score≥4 and Staging score up to 3 (Ishak) at 1 year after liver transplantation., Methods: Seventy-three consecutive patients with mild/moderate recurrence were randomized either to no treatment or to receive Pegilated-Interferon-alfa-2b and ribavirin for 52 weeks. Liver biopsies obtained at baseline (1 year after transplantation) and 2 years afterwards were evaluated for assessment of disease progression, defined as worsening of at least 2 staging points or progression to stage 4 or higher., Results: As for these two major histological end points there were no statistically significant differences between the 2 groups (36.1% vs. 50%, p=0.34 and 36.1% vs. 38.9%, p=1). Fifteen treated patients (41%) achieved a sustained virological response which was associated with a reduced risk of fibrosis worsening for both endpoints when compared to viremic patients (p=0.04)., Conclusions: Although antiviral-therapy was beneficial in preventing fibrosis progression in patients achieving a sustained virological response, the majority of the overall population of our patients with mild-moderate disease recurrence could not benefit from antiviral therapy either because they either could not be treated or did not respond to treatment (EudraCT number: 2005-005760)., (Copyright © 2012. Published by Elsevier Ltd.)
- Published
- 2012
- Full Text
- View/download PDF
11. Cost analysis of living donor liver transplantation: the first Italian economical data.
- Author
-
Passarani S, De Carlis L, Maione G, Alberti AB, Bevilacqua L, and Baraldi S
- Subjects
- Costs and Cost Analysis, Hematologic Tests, Humans, Italy, Liver Transplantation statistics & numerical data, Liver Transplantation economics, Living Donors statistics & numerical data
- Abstract
Background: Over a period of 30 months, the Niguarda Ca'Granda Hospital performed 12 living donor liver transplants (LDLT) on adult subjects using the split-liver technique and transplant of the right lobe. The purpose of this work is to evaluate the financial obligation that this technique will bring, the ethical and cultural aspects, and the mortality related to surgery on a healthy donor whose only reward is in the knowledge of having done everything possible for a loved family member., Methods: The analysis of the costs of the surgical process takes into account the simultaneous consideration of both types of patients: the donor and the recipient. The diagnostic course is subdivided into seven functional phases of the cost centers, and the transitory sequences of the foreseeable events of the entire process. The method used consists in the appraisal of all the clinical activities in chronological order several the centers of cost. The direct expenses are evaluated according to an analytical method, and the indirect costs has been carried out on the criterion of the activities of support to the process (management of the orders, recording and programming of the activities) and support to the organization (maintenance, management supplying and contests of contract, programming of the business production, management warehouses, supplyings, marketing and relations with the public)., Results: The cost of all the patients evaluated that were not able to donate has been added to the direct expenses of 12 donor and 12 recipient patients, in all 30 patients, so as to shift the added expenses only to the donor patient, since these costs are not included in the typical costs of transplantation from a cadaver. The indirect cost calculated for each patient has been added to the direct costs of the donor and recipient patients. The total calculated cost of LDLT is 175, 210.78 Euros., Conclusion: The analysis of the economical obligation that this practice brings is the starting point for an accurate evaluation of all the new technology that, in conjunction with the results of clinical efficacy and efficiency trials, is part of program of a larger scope to fulfil the general social principles of equity and justice.
- Published
- 2007
12. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study.
- Author
-
Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Cammà C, De Carlis L, Minola E, Quaglia A, Zavaglia C, Vangeli M, Patch D, Dhillon A, Cillo U, Guido M, Fagiuoli S, Giacomoni A, Slim OA, Airoldi A, Boninsegna S, Davidson BR, Rolles K, and Pinzello G
- Subjects
- Adult, Age Factors, Cohort Studies, Disease Progression, Female, Hepatitis C physiopathology, Humans, Kaplan-Meier Estimate, Liver Cirrhosis physiopathology, Longitudinal Studies, Male, Middle Aged, Recurrence, Retrospective Studies, Risk Factors, Severity of Illness Index, Sex Factors, Time Factors, Tissue Donors, Hepatitis C complications, Liver Cirrhosis surgery, Liver Cirrhosis virology, Liver Transplantation
- Abstract
In recent years, a worsening outcome of hepatitis C virus (HCV)-positive recipients and a faster progression of recurrent disease to overt cirrhosis has been reported. Our aims were to 1) assess patient survival and development of severe recurrent disease (Ishak fibrosis score > 3) in different transplant years; and 2) model the effects of pre- and post-liver transplantation (LT) variables on the severity of recurrent disease. A multicenter retrospective analysis was conducted on 502 consecutive HCV-positive transplant recipients between January 1990 and December 2002. Protocol liver biopsies were obtained at 1, 3, 5, 7, and 10 yr post-LT in almost 90% of the patients. All 502 patients were included in the overall survival analysis, while only the 354 patients with a follow-up longer than 1 yr were considered for the analysis of predictors of disease progression. The overall Kaplan-Meier survival rates were 78.7%, 66.3%, and 58.6%, at 12, 60, and 120 months, respectively, and a trend for a better patient survival over the years emerged from all 3 centers. The cumulative probability of developing HCV-related recurrent severe fibrosis (Ishak score 4-6) in the cohort of 354 patients who survived at least 1 yr remained unchanged over the years. Multivariate analysis indicated that older donors (P = 0.0001) and female gender of recipient (P = 0.02) were the 2 major risk factors for the development of severe recurrent disease, while the adoption of antilymphocytic preparations was associated with a less aggressive course (P = 0.03). Two of these prognostic factors, donor age and recipient gender, are easily available before LT and their combination showed an important synergy, such that a female recipient not only had a much higher probability of severe recurrent disease than a male recipient but her risk increased with the increasing age of the donor, reaching almost 100% when the age of the donor was 60 or older. In conclusion, a trend for a better patient survival was observed in more recent years but the cumulative probability of developing severe recurrent disease remained unchanged. The combination of a female recipient receiving an older graft emerged as a strong risk factor for a severe recurrence.
- Published
- 2007
- Full Text
- View/download PDF
13. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma.
- Author
-
Zavaglia C, De Carlis L, Alberti AB, Minola E, Belli LS, Slim AO, Airoldi A, Giacomoni A, Rondinara G, Tinelli C, Forti D, and Pinzello G
- Subjects
- Adult, Age Factors, Analysis of Variance, Carcinoma, Hepatocellular pathology, Cohort Studies, Female, Graft Rejection, Graft Survival, Humans, Italy, Liver Neoplasms pathology, Liver Transplantation methods, Male, Middle Aged, Neoplasm Staging, Predictive Value of Tests, Probability, Proportional Hazards Models, Retrospective Studies, Risk Assessment, Sex Factors, Statistics, Nonparametric, Survival Analysis, Time Factors, Transplantation Immunology physiology, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular surgery, Cause of Death, Liver Neoplasms mortality, Liver Neoplasms surgery, Liver Transplantation mortality
- Abstract
Aims: The aim of this study was to identify predictors of both survival and tumor-free survival of a cohort of 155 patients, with hepatocellular carcinoma (HCC) and cirrhosis, who were treated by orthotopic liver transplantation (OLT)., Methods: From January 1989 to December 2002, 603 OLTs were performed in 549 patients. HCC was diagnosed in 116 patients before OLT and in 39 at histological examination of the explanted livers. Eighty-four percent of the patients met "Milan" criteria at histology. Ninety-four patients received anticancer therapies preoperatively., Results: The median follow-up was 49 months (range, 0-178). Overall, 1-, 3-, 5-, and 10-yr survival were 84%, 75%, 72%, and 62%, respectively. Survival was not affected by the patient's age or sex, etiology of liver disease, Child score at transplantation, rejection episodes, tumor number, total tumor burden, bilobar tumor, and pathologic Tumor, Nodes, Metastasis (pTNM) stages. There was no statistically significant difference in survival when patients were grouped according to the recently proposed simplified pTNM staging (5-yr survival, 80% in stage I, 69% in stage II, 50% in stage III, p= 0.3) or the United Network for Organ Sharing (UNOS) staging system for HCC. Encapsulation of the tumor and alpha-fetoprotein levels significantly affect patient survival. Five-year survival of patients with poorly differentiated (G3) HCC was significantly worse than that of patients with moderately (G2) or well-differentiated (G1) HCC (respectively, G3 44%, G2 67%, and G1 97%, p= 0.0015). Patients with micro- or macro-vascular invasion had a worse 5-yr survival than patients without vascular invasion (49%vs 77%, p= 0.04). Multivariate analysis showed that histological grade of differentiation and macroscopic vascular invasion are independent predictors of survival (HR 2.4, 95% CI 1.4-4.1, p= 0.0009 and HR 2.8, 95% CI 1.2-6.8, p= 0.022)., Conclusion: Histological grade of differentiation and macroscopic vascular invasion, as assessed on the explanted livers, are strong predictors of both survival and tumor recurrence in patients with cirrhosis who received transplants for HCC.
- Published
- 2005
- Full Text
- View/download PDF
14. Sequence variation in the hypervariable region 1 of hepatitis C virus and posttransplantation recurrent hepatitis.
- Author
-
Silini E, Belli L, Brambilla S, Foti L, Gritti C, Lisa A, Alberti AB, Vinci M, De Carlis L, Rondinara G, and Pinzello G
- Subjects
- Adult, Cloning, Molecular, Female, Hepacivirus growth & development, Humans, Male, Middle Aged, Phylogeny, Postoperative Complications virology, Recurrence, Virus Replication, Hepacivirus genetics, Hepatitis C, Chronic surgery, Hepatitis C, Chronic virology, Liver Transplantation, Viral Proteins genetics
- Abstract
Hepatitis C virus (HCV) shows remarkable genetic variation in both populations and individuals, in whom it circulates as quasispecies (QS). Sequence variation within an infected host has adaptive significance and reflects the modes and intensity of selection mechanisms operating on the virus. We investigated the sequence diversity of hypervariable region 1 of HCV in liver transplant recipients and correlated it with the recurrence of hepatitis. Twenty-six patients were considered during a 2-year period; all had graft reinfection, and 14 patients developed hepatitis recurrence. Cloned sequences were obtained from sera collected before or within 1 month after orthotopic liver transplantation (OLT) and at 3 and 24 months thereafter. Sequence diversity within single sera and over consecutive samples was analyzed quantitatively by matrix comparison and phylogenetic analysis. Propagation of viral QS in the graft was markedly dependent on individual factors. Viral QS in post-OLT sera were less complex and evolved slower compared with immunocompetent subjects with chronic hepatitis. Sequence variation was greater during the first 3 months post-OLT than during the remaining period. Genetic diversity within single samples was not related to hepatitis recurrence or other clinical features. Conversely, sequence diversity over consecutive samples was reduced in patients who experienced hepatitis recurrence, in particular, in those infected with genotype 1b and with an HLA-DR mismatched graft. Selection of viral sequences was markedly impaired in liver transplant recipients and tended to be greater early after OLT. Reduced sequence turnover correlated negatively with the outcome of graft reinfection.
- Published
- 2003
- Full Text
- View/download PDF
15. Tapering off steroids three months after liver transplantation is not detrimental for hepatitis C virus disease recurrence.
- Author
-
Belli LS, Alberti AB, Vangeli M, Airoldi A, and Pinzello G
- Subjects
- Disease Progression, Dose-Response Relationship, Drug, Drug Administration Schedule, Humans, Recurrence, Adrenal Cortex Hormones administration & dosage, Hepatitis C physiopathology, Liver Transplantation, Postoperative Care
- Published
- 2003
- Full Text
- View/download PDF
16. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study.
- Author
-
Alberti AB, Belli LS, Airoldi A, de Carlis L, Rondinara G, Minola E, Vangeli M, Cernuschi A, D'Amico M, Forti D, and Pinzello G
- Subjects
- Administration, Oral, Adult, Aged, Cohort Studies, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Injections, Subcutaneous, Liver Cirrhosis surgery, Liver Cirrhosis virology, Liver Transplantation methods, Male, Middle Aged, Postoperative Complications drug therapy, Recurrence, Statistics, Nonparametric, Treatment Outcome, Antiviral Agents administration & dosage, Hepatitis C, Chronic diagnosis, Hepatitis C, Chronic drug therapy, Interferon-alpha administration & dosage, Liver Transplantation adverse effects, Ribavirin administration & dosage
- Abstract
Recurrent hepatitis C is a common problem after liver transplantation that can progress to liver cirrhosis of the graft. Preliminary reports of combination treatment with interferon (IFN) and ribavirin have been promising, but long-term follow-up data are not yet available. We report our experience with 1 year of combination therapy with IFN (3 million units thrice weekly) and low-dose ribavirin (600 mg/d), followed by long-term ribavirin monotherapy in 18 patients with moderate to severe recurrent hepatitis C and a median follow-up of 32 months after the completion of combined therapy. All patients were followed up clinically and histologically at regular intervals. Overall, in an intention-to-treat analysis, 15 patients had normal alanine aminotransferase levels (biochemical end-treatment response [ETR], 83%), and 8 patients were also hepatitis C virus RNA negative in serum (virological ETR, 44%) at the end of combined treatment. At last follow-up after the completion of combined therapy (median, 32 months; range, 18 to 73 months), 13 patients were biochemical responders (biochemical long term-sustained response [LT-SR], 72%), and 5 patients also maintained viral clearance (virological LT-SR, 27%). Comparison of liver biopsy specimens before and after 12 months of combined therapy showed improvement in grading scores of at least two points in the majority of the patients (73%). Notably, a trend toward fibrotic progression was only noted in nonresponders. Regarding side effects, despite the low dose of ribavirn, almost half the patients developed hemolytic anemia requiring dose reductions. In addition, long-term ribavirin monotherapy was not associated with iron accumulation. We conclude that combined therapy with low-dose ribavirin followed by long-term ribavirin monotherapy can be recommended because it favorably modifies the natural history of recurrent hepatitis C in most patients and possibly halts histological disease progression without causing iron accumulation.
- Published
- 2001
- Full Text
- View/download PDF
17. Early ribavirin treatment and avoidance of corticosteroids in hepatitis C virus (HCV)-positive liver transplant recipients: interim report of a prospective randomized trial.
- Author
-
Belli LS, Alberti AB, Rondinara GF, de Carlis L, Corti A, Mazza E, Airoldi A, Cernuschi A, de Gasperi A, Forti D, and Pinzello GB
- Subjects
- Drug Administration Schedule, Follow-Up Studies, Hepatitis C enzymology, Humans, Interferons therapeutic use, Liver enzymology, Postoperative Complications prevention & control, Prospective Studies, Secondary Prevention, Adrenal Cortex Hormones administration & dosage, Antiviral Agents therapeutic use, Hepatitis C prevention & control, Liver Transplantation immunology, Ribavirin therapeutic use
- Published
- 2001
- Full Text
- View/download PDF
18. Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation.
- Author
-
Belli LS, Zavaglia C, Alberti AB, Poli F, Rondinara G, Silini E, Taioli E, de Carlis L, Scalamogna M, Forti D, Pinzello G, and Idèo G
- Subjects
- Adult, Alleles, Disease Progression, Female, Gene Frequency, Hepatitis C drug therapy, Hepatitis C physiopathology, Histocompatibility Antigens Class I genetics, Histocompatibility Antigens Class II genetics, Humans, Immunogenetics, Male, Middle Aged, Multivariate Analysis, Recurrence, Hepatitis C genetics, Hepatitis C immunology, Liver Transplantation, Postoperative Complications
- Abstract
In immunocompetent patients, specific human leukocyte antigen (HLA) class II alleles have been associated with the severity of hepatitis C virus (HCV)-related disease, in particular, HLA-DRB1*11 has been found to exert a protective effect. The authors have analyzed the role of HLA class I and II alleles in determining the frequency, timing, and progression of histologically proven recurrent hepatitis C in 89 patients who underwent a liver transplant for HCV-related cirrhosis. In addition, the influence of HLA mismatch between donor and recipient, HCV genotype, and use of steroid pulses was also evaluated. Median patient follow up was 35 months (range 4-119). HLA-DRB1 typing was performed by genomic analysis in all cases. Liver biopsies were obtained routinely and at least at yearly intervals. Histologically proven recurrent hepatitis was observed in 46 patients (52%), 10 patients progressing to stage 5-6 fibrosis in most cases within 2 years after transplant. By univariate analysis, 3 variables, HLA-B14, HLA-DRB1*04, and HLA-DRB1 donor/recipient mismatch, showed a significant effect on time to recurrent hepatitis C disease. These parameters were included in a multivariate regression model along with HCV genotype, treatment with steroid pulses and DRB1*11. HLA-B14, HLA-DRB1*04, and HLA-DRB1 donor/recipient mismatch were confirmed to provide a significant and independent contribution to the risk of hepatitic disease recurrence. As for the severity of the disease, none of the 10 patients with stage 5-6 hepatitis carried the HLA-DRB1*11 allele, in line with what was observed in nontransplant subjects. Our results suggest that in posttransplant recurrent hepatitis C, immunogenetic factors are relevant in determining HCV infection outcome.
- Published
- 2000
- Full Text
- View/download PDF
19. Immunogenetic factors, HCV genotypes, and HCV recurrence after liver transplantation.
- Author
-
Belli LS, Zavaglia C, Alberti AB, Rondinara GF, De Carlis L, Silini E, Poli F, Scalamogna M, Tinelli C, Forti D, and Ideo G
- Subjects
- Alleles, Follow-Up Studies, Genotype, Graft Survival, HLA-DR Antigens genetics, HLA-DR Antigens immunology, HLA-DRB1 Chains, Hepacivirus isolation & purification, Hepatitis C complications, Histocompatibility Testing, Humans, Liver Cirrhosis etiology, Liver Cirrhosis surgery, Postoperative Complications, Recurrence, Retrospective Studies, Time Factors, Hepacivirus genetics, Hepatitis C diagnosis, Hepatitis C surgery, Liver Transplantation immunology
- Published
- 1999
- Full Text
- View/download PDF
20. HGV/GBV-C infection in liver transplant recipients: antibodies to the viral E2 envelope glycoprotein protect from de novo infection.
- Author
-
Silini E, Belli L, Alberti AB, Asti M, Cerino A, Bissolati M, Rondinara G, De Carlis L, Forti D, Mondelli MU, and Ideo G
- Subjects
- Adult, Female, Hepatitis C etiology, Hepatitis, Viral, Human immunology, Humans, Male, Middle Aged, RNA, Viral analysis, Recurrence, Flaviviridae immunology, Hepatitis Antibodies blood, Hepatitis, Viral, Human etiology, Liver Transplantation adverse effects, Viral Envelope Proteins immunology
- Abstract
Background/aims: Liver transplantation for endstage liver cirrhosis provides a useful model to investigate the pathogenetic role of hepatotropic viral agents. Recently, a new member of the Flaviviridae family, provisionally named HGV/GBV-C virus, has been associated with acute and chronic non A-E hepatitis. We studied 136 patients with cirrhosis consecutively transplanted at our institution for evidence of hepatitis G virus infection and correlation with the patients' clinical course., Methods: All patients survived for at least 6 months after transplantation (median follow-up 44 months) and underwent routine liver biopsies. Hepatitis G virus infection was studied using both direct viral RNA identification by RT-PCR and indirect detection of antibodies to the E2 glycoprotein., Results: There was a high frequency of the hepatitis G virus among patients undergoing liver transplantation, with HGV RNA and anti-E2 prevalence rates of 18.4% and 26.5%, respectively. HGV RNA prevalences significantly increased after transplantation (47.8%), with 47.3% rate of new infections in susceptible subjects. Anti-E2 antibodies were significantly more prevalent among patients transplanted for HCV-related cirrhosis and represented a strong protective factor against hepatitis G virus reinfection or recurrent infection. No correlation was found between HGV RNA or anti-E2 prevalences and survival after transplantation or rates of recurrent liver damage., Conclusions: All available evidence suggests that, although liver transplant patients are heavily exposed to hepatitis G virus both before and after transplantation, hepatitis G virus does not induce liver disease in this setting. Most infections appear to be self-limited and induce a protective immunity which is marked by the presence of anti-E2 antibodies.
- Published
- 1998
- Full Text
- View/download PDF
21. Early cyclosporine monotherapy in liver transplantation: a 5-year follow-up of a prospective, randomized trial.
- Author
-
Belli LS, de Carlis L, Rondinara G, Alberti AB, Bellati G, De Gasperi A, Forti D, and Idèo G
- Subjects
- Adult, Cyclosporine adverse effects, Follow-Up Studies, Humans, Immunosuppressive Agents adverse effects, Prospective Studies, Transplantation, Homologous, Treatment Outcome, Cyclosporine administration & dosage, Graft Rejection prevention & control, Immunosuppressive Agents administration & dosage, Liver Transplantation
- Abstract
Maintenance of adequate immunosuppression and avoidance of side-effects are the goals of long-term management of all organ-transplanted patients. We here report the final results of a prospective, randomized trial comparing early cyclosporine monotherapy versus double-drug therapy (cyclosporine and steroids) in adult liver transplantation patients. One hundred four patients were randomized 3 months after transplantation either to continue (Group I = 50 patients) or to stop steroids (Group II = 54 patients). Patients on a double-drug regimen were maintained long term on methylprednisolone at a dose of 0.1 mg/kg/d. Target cyclosporine trough levels were between 150 and 250 ng/mL in both groups. Our main points of interest were the prevalence of acute and chronic rejections and steroid-related side-effects in the two groups of patients. Mean follow-up was 41 +/- 16 months (range, 4-68 months). Patient actuarial survival 2 and 5 years after randomization was similar in the two groups (82% vs. 83% and 82% vs. 77%). The prevalence of acute rejections after randomization was, respectively, 8% and 4%. A single episode of chronic rejection was observed only in a patient on long-term steroid therapy. Side-effects of steroid therapy were less frequent in patients weaned off steroids, and when considering hypertension and diabetes, the differences between the two groups were statistically significant. Early cyclosporine monotherapy is a safe undertaking in liver transplantation because it allows a significant reduction of steroid-related side-effects without increasing the risk of acute and chronic rejection. After 5 years, patient survival was similar in patients with or without steroids.
- Published
- 1998
- Full Text
- View/download PDF
22. Both immunogenetic factors and HCV genotype can influence the outcome of chronic HCV infection.
- Author
-
Zavaglia C, Belli LS, Alberti AB, Ideo G, and Silini E
- Subjects
- Carrier State immunology, Carrier State virology, Chronic Disease, Disease Progression, Female, Genotype, Hepatitis C virology, Humans, Male, Middle Aged, Hepacivirus genetics, Hepatitis C immunology
- Published
- 1997
23. Hepatitis C virus genotypes and severe hepatitis C virus recurrence after liver transplantation.
- Author
-
Alberti AB, Belli LS, Silini E, Zavaglia C, Iamoni G, Rondinara GF, De Carlis L, Forti D, and Ideo G
- Subjects
- Biopsy, Follow-Up Studies, Genotype, Hepacivirus isolation & purification, Hepatitis C pathology, Humans, Liver Function Tests, Predictive Value of Tests, RNA, Viral analysis, Recurrence, Retrospective Studies, Survival Rate, Time Factors, Hepacivirus genetics, Hepatitis C physiopathology, Hepatitis C surgery, Liver Transplantation mortality, Liver Transplantation pathology
- Published
- 1997
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.